logo

For the Inventor, By the Inventor

Birmingham, United Kingdom

Gurdyal S Besra

This inventor holds 11 USPTO granted patents and 1 published patent application, plus 1 CIPO patent. Top assignees: Ludwig Institute for Cancer Research Limited, The University of Birmingham, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2011-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gurdyal S Besra. Retrieved from https://idiyas.com/inventor/gurdyal-s-besra

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 

% Patents Active = 81.8


Average Co-Inventor Count = 4.4

ph-index = 3

Forward Citations = 48(Granted Patents)


Location History:

  • Solihull, GB (2013 - 2014)
  • West Midlands, GB (2015 - 2016)
  • Birmingham, GB (2011 - 2020)

Company Filing History:

goldMedal7 out of 530 
 
Ludwig Institute for Cancer Research Limited
 patents
silverMedal5 out of 125 
 
The University of Birmingham
 patents
bronzeMedal3 out of 3,696 
 
The United States of America, as Represented by the Secretary, Department of Health and Human Services
 patents
4. 2 out of 484 
 
Oxford University Innovation Ltd
 patents
5. 1 out of 55 
 
Statens Serum Institute
 patents
where one patent can have more than one assignee

Years Active: 2011-2020

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents
1. 10765648 - iNKT cell modulators and methods of using the same (2020-09-08),
2. 10314796 - iNKT cell modulators and methods of using the same (2019-06-11),
3. 9700532 - iNKT cell modulators and methods of using the same (2017-07-11),
4. 9517243 - Beta-mannosylceramide and stimulation of NKT cell anti-tumor immunity (2016-12-13),
5. 9365496 - iNKT cell modulators and methods of using the same (2016-06-14),
6. 9168291 - β-mannosylceramide and stimulation of NKT cell anti-tumor immunity (2015-10-27),
7. 8835613 - β-mannosylceramide and stimulation of NKT cell anti-tumor immunity (2014-09-16),
8. 8563009 - Use of monomycolyl glycerol (MMG) as an adjuvant (2013-10-22),
9. 8334408 - Analogs of alpha galactosylceramide and uses thereof (2012-12-18),
10. 8188313 - Analogs of alpha galactosylceramide and uses thereof (2012-05-29),
11. 8039670 - Analogs of alpha galactosyceramide and uses thereof (2011-10-18),

Title: Gurdyal S Besra: Innovator in iNKT Cell Modulation

Introduction

Gurdyal S Besra is a prominent inventor based in Birmingham, GB. He has made significant contributions to the field of immunology, particularly in the development of iNKT cell modulators. With a total of 11 patents to his name, Besra's work has the potential to impact various therapeutic approaches.

Latest Patents

Among his latest patents, Besra has disclosed innovative methods involving α-galactosylceramide (α-GalCer) analogs. These compositions are designed to activate invariant Natural Killer T (iNKT) cells. His patents detail methods for treating diseases by utilizing these analogs and explore combination therapies that enhance their effectiveness.

Career Highlights

Gurdyal S Besra has worked with notable institutions such as the Ludwig Institute for Cancer Research Limited and the University of Birmingham. His research has focused on advancing our understanding of immune responses and developing novel therapeutic strategies.

Collaborations

Some of his notable coworkers include Vincenzo Cerundolo and Liam R Cox. Their collaborative efforts have contributed to the advancement of research in the field of immunology.

Conclusion

Gurdyal S Besra's innovative work in iNKT cell modulation showcases his dedication to advancing medical science. His contributions through patents and collaborations highlight the importance of research in developing new therapeutic options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…